This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human Osteoactivin / GPNMB Protein, His Tag
catalog :
GPB-H5229
quantity :
100 ug, 1 mg
price :
260 USD, 1600 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
GPB-H5229
product name :
Human Osteoactivin / GPNMB Protein, His Tag
quantity :
100 ug, 1 mg
price :
260 USD, 1600 USD
quantity & price :
$260/100ug,$1600/1mg
target :
Osteoactivin
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human Osteoactivin, His Tag (GPB-H5229) is expressed from human 293 cells (HEK293). It contains AA Ala 22 - Pro 486 (Accession # AAH32783).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human Osteoactivin, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Transmembrane glycoprotein NMB (GPNMB) is also known as Transmembrane glycoprotein HGFIN, DC-HIL and Osteoactivin (OA), which belongs to the PMEL/NMB family. GPNMB contains one PKD domain. GPNMB is a transmembrane glycoprotein that is up-regulated in various cancer cells, including in glioblastoma multiforme and is expressed in many melanoma cells, as well as in tissue macrophages. GPNMB protein acts as a downstream mediator of BMP-2 effects on osteoblast differentiation and function. GPNMB participates in bone mineralization, and functions as a negative regulator of inflammation in macrophages.
References :
(1) Weterman MA., et al., 1995, International Journal of Cancer 60 (1): 73–81.
(2) Abdelmagid, SM., et al., 2008, Exp Cell Res 314 (13): 2334–51.
(3) Abdelmagid SM., et al., 2007, J Cell Physiol. 210 (1): 26–37.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments